Earn CME/CE in your profession:

Continuing Education Activity

Fluorescein is a diagnostic contrast agent particularly used in various ophthalmic procedures, such as checking for any corneal or vessel abnormalities. The application of fluorescein also extends to bioimaging whole anatomic structures and even further to cellular components in immunohistological staining. This article outlines the indications, mechanism of action, adverse event profile, and contraindications for fluorescein to guide the healthcare team in evaluating ophthalmic abnormalities, infection, and pathophysiology, among other conditions.


  • Identify the mechanism of action of fluorescein.
  • Describe the possible adverse effects of fluorescein.
  • Review the appropriate monitoring for patients receiving fluorescein.
  • Summarize interprofessional team strategies for improving care coordination and communication to advance fluorescein and improve outcomes.


Fluorescein is an organic compound used as a dye, particularly as a fluorescent agent in diagnostic procedures at various levels.


  • Fluorescein has extensive use in routine ophthalmic tests. This usage ranges from applanation tonometry, gonioscopy, and contact lens fittings to angioscopy/angiography of retina and iris vasculature. In the first scenario, after an anesthetic and a fluorescein strip are applied to the eyes, a tonometer is placed on the cornea to determine the intraocular pressure of one eye at a time. Applanation tonometry utilizes fluorescein to produce semicircles that aid in the measurement of the dial reading. For improved detection of any breaks in the vasculature or associated retinal conditions, fluorescein angiography stains the blood vessels of the retina and iris to provide a detailed image of the posterior view of the eye. One study on retinopathy of prematurity (ROP) relies on fluorescein angiography to evaluate treatment efficacy between two different drugs on peripheral retina vasculature. Unlike plain fundus photographs, fluorescein angiography also pinpointed vascular loops, blunting, dilatation, and capillary dropout.[1][2][1]
  • Additionally, fluorescein produces remarkable contrast to determine if any corneal abrasions, epithelial keratitis, herpes simplex keratitis, or corneal foreign bodies are present. If the epithelium of the cornea is not intact, aqueous humor leaks through and mixes with the fluorescein dye to reveal a corneal abrasion or other corneal abnormalities. In a study assessing dry eyes, fluorescein was useful in measuring the stability of the tear film. Despite any significant differences between using a standard strip or small volumes of liquid dye, fluorescein proved effective in augmenting any breaks in the tear film that occurs in dry eye disease.[3][4][3]


  • The remarkable fluorescence of fluorescein permits considerable insight into the identification of non-diseased tissues, tumor-affected tissues, or histological markers. For example, fluorescein can serve as a contrast agent in surgical procedures for nonspecific identification of anatomic arrangements. Fluorescence of healthy tissue of the focused region differentiates it from nearby normal tissues and aids the surgeon in removing or repairing necessary tissues while also protecting vital structures. A surgery to repair hand anatomy may need fluorescein to highlight the nerves specific for fine motor skills or differentiate blood vessels of a particular section.[5]
  • Furthermore, in a microendoscopy study to find dysplasia in colorectal tissue, fluorescein was preferred to proflavine, especially due to its ability to highlight crypt structures with greater sensitivity, intensity, and uniformity. Identification of structures on a deeper, finer level expands the nonspecific functionality of fluorescein and eases the process of diagnostic procedures.[6] Its range of use can be from a bundle of nerves to an individual blood vessel, further to tissue abnormalities, and even further to the molecular level.

Conjugate Species/Biomarker

  • Fluorescent microscopy allows for the identification of microorganisms or cellular components, such as proteins, in immunohistological staining. In the most common indirect method of immunohistochemistry, the enzyme-linked immunosorbent assay (ELISA) uses fluorescein to act as a fluorescent conjugated to secondary antibodies. Moreover, certain compounds commonly modify or combine with the original fluorescein structure to adjust the attachment of the fluorescent tag to specific macromolecules. The combination of water-soluble chitosan derivative with a fluorescent tag created glycol chitosan fluorescein-isothiocyanate (GC-FITC), which showed to be a sufficient agent used for bio-imaging when compared to its commercial equivalents. Even at a lower concentration, the biocompatibility of the molecule as well as the strong affinity to the cell surface, through a strong electrostatic interaction, offer efficient cell staining, namely, for the identification of lipid rafts.[7]
  • On a clinical level, a cardiology study exhibits the use of fluorescein as a fluorescent tag/biomarker in cardioscopy for the detection/monitoring of coronary artery disease (CAD). Fluorescein is injected into the circulatory system, and its fluorescence is observable throughout cardiomyocytes in terms of tissue fluid flow. Through molecular bioimaging, fluorescein plays a role in the status of patients with CAD experiencing angina pectoris or other cardiovascular issues or who have undergone treatment with stents.[8]

Mechanism of Action

As an ocular disclosing agent, fluorescein sodium dissolves readily in aqueous alkaline solutions, responds to 465 to 490 nm at cobalt blue light, and fluoresces at 520 to 530 nm as bright green. The compound contains a conjugated system that illuminates when electrons spend a prolonged time in an excited state. It is often administered in combination with a local anesthetic such as proparacaine or benzoxinate, which inhibits sodium ion channels to stabilize nerve cell membranes to inhibit nerve impulse conduction.

When using fluorescein to stain cells, its charged ends become attracted to the hydrophilic ends in the cell membrane to form a strong electrostatic bond. One or more of the charged ends of fluorescein may then be modified for greater interaction.[7]


Ophthalmic administration of fluorescein starts with a paper strip with one tip stained with fluorescein. The paper strip is moistened with saline water, then placed on the conjunctiva or inferior fornix. The patient may blink a few times to spread the dye across the eye.

For ocular foreign body removal, the clinician should instill 1 or 2 drops in the eyes pre-procedural.

Fluorescein solution may be administered orally and requires 10 to 15 minutes before appearing. Although the solution is bitter, combining it with sugar or a beverage can increase palatability.

Intravenous injection of fluorescein sodium occurs at the antecubital vein. The dye appears almost immediately in the retina and choroidal vessels (in 7 to 14 seconds). In the case of anaphylaxis, IV access is still necessary for epinephrine. 

After the administration of fluorescein, the examiner can extinguish the room light to view the fluorescence of the dye under cobalt blue light.[9]

Adverse Effects

Common: paresthesia of lips, change in taste (orally), severe eye-stinging and irritation (ophthalmic), severe nausea, vomiting, abdominal pain, chest pain, and extravasation.

  • Mild: urine discoloration, skin inflammation/discoloration at the injection site 
  • Moderate: rashes, urticaria, syncope/dizziness/hypotension, angioedema, chest pain
  • Severe: nerve palsy, seizure, bronchospasm, pulmonary edema, epithelial keratopathy, anaphylaxis[9]

Corneal opacification can occur with prolonged use.


Hypersensitivity to fluorescein formulation prevents its application. Furthermore, even though more research is needed to determine side effects on a fetus, pregnancy may be considered a relative contraindication, although based on the drug's pharmacology and limited systemic absorption, no fetal harm is expected.[9] Likewise, the drug may be used during breastfeeding even in the absence of any human data, as no harm to the infant or impact on maternal milk production is expected based on pharmacological properties.

If the formulation includes an ester anesthetic, as is often the case, hypersensitivity to such agents is also a contraindication. Other conatrinindicaitons include sensitivity to PABA (para-aminobenzoic acid) and prolonged use.


Fluorescein has no known significant drug interactions. Under ophthalmic examination, contact lens removal is necessary with the use of fluorescein to avoid unnecessary staining.[2] Fluorescein completely clears through urine excretion 2 to 3 days after injection.[9] There are no recommended routine testing or lab values.


Fluorescein toxicity is low. Proper doses of epinephrine and antihistamines can manage cases of significant hypersensitivity after flushing the affected area with plenty of water. Prevention of anaphylaxis is possible by providing a minimal dose of fluorescein to determine if a minor reaction would occur.

If enough fluorescein is issued intravenously, precaution is necessary for nursing mothers because another route of excretion is through human milk, causing it to turn yellow.[10]

Enhancing Healthcare Team Outcomes

Because fluorescein administration is for diagnostic purposes, its use is most commonly by specialists, especially ophthalmologists and surgeons, as well as optometrists, but it is also used by general practitioners, including physicians, nurse practitioners, and physician assistants. Nurses and/or medical assistants may also assess the proper dosage for the desired procedure. Not all health professionals readily operate with a fluorescent agent. Nurses can assist in the procedure via preparation, monitoring for adverse effects, and post-procedural care. Interprofessional coordination between the various members of the healthcare team will result in optimal results when using fluorescein for diagnostic purposes, which in turn can lead to appropriate therapeutic intervention and improved patient outcomes. [Level 5]



Mayur Parmar


5/29/2023 4:59:28 PM



Jin E, Yin H, Gui Y, Chen J, Zhang J, Liang J, Li XX, Zhao M. Fluorescein Angiographic Findings of Peripheral Retinal Vasculature after Intravitreal Conbercept versus Ranibizumab for Retinopathy of Prematurity. Journal of ophthalmology. 2019:2019():3935945. doi: 10.1155/2019/3935945. Epub 2019 Dec 31     [PubMed PMID: 31976086]


Fernández-Jimenez E, Diz-Arias E, Peral A. Improving ocular surface comfort in contact lens wearers. Contact lens & anterior eye : the journal of the British Contact Lens Association. 2022 Jun:45(3):101544. doi: 10.1016/j.clae.2021.101544. Epub 2021 Nov 25     [PubMed PMID: 34840071]


Paugh JR, Tse J, Nguyen T, Sasai A, Chen E, De Jesus MT, Kwan J, Nguyen AL, Farid M, Garg S, Jester JV. Efficacy of the Fluorescein Tear Breakup Time Test in Dry Eye. Cornea. 2020 Jan:39(1):92-98. doi: 10.1097/ICO.0000000000002148. Epub     [PubMed PMID: 31513046]


Naik K, Magdum R, Ahuja A, Kaul S, S J, Mishra A, Patil M, Dhore DN, Alapati A. Ocular Surface Diseases in Patients With Diabetes. Cureus. 2022 Mar:14(3):e23401. doi: 10.7759/cureus.23401. Epub 2022 Mar 22     [PubMed PMID: 35495002]


Orosco RK, Tsien RY, Nguyen QT. Fluorescence imaging in surgery. IEEE reviews in biomedical engineering. 2013:6():178-87. doi: 10.1109/RBME.2013.2240294. Epub 2013 Jan 15     [PubMed PMID: 23335674]


Prieto SP, Lai KK, Laryea JA, Mizell JS, Mustain WC, Muldoon TJ. Fluorescein as a topical fluorescent contrast agent for quantitative microendoscopic inspection of colorectal epithelium. Biomedical optics express. 2017 Apr 1:8(4):2324-2338. doi: 10.1364/BOE.8.002324. Epub 2017 Mar 24     [PubMed PMID: 28736674]


Kim HC, Park WH. Fluorescent property of glycol chitosan-fluorescein isothiocyanate conjugate for bio-imaging material. International journal of biological macromolecules. 2019 Aug 15:135():1217-1221. doi: 10.1016/j.ijbiomac.2019.06.038. Epub 2019 Jun 8     [PubMed PMID: 31181277]


Uchida Y, Uchida Y. Dye-Staining Angioscopy for Coronary Artery Disease. Current cardiovascular imaging reports. 2015:8(4):10     [PubMed PMID: 25750692]


Kornblau IS, El-Annan JF. Adverse reactions to fluorescein angiography: A comprehensive review of the literature. Survey of ophthalmology. 2019 Sep-Oct:64(5):679-693. doi: 10.1016/j.survophthal.2019.02.004. Epub 2019 Feb 14     [PubMed PMID: 30772364]

Level 3 (low-level) evidence


Samples JR, Meyer SM. Use of ophthalmic medications in pregnant and nursing women. American journal of ophthalmology. 1988 Nov 15:106(5):616-23     [PubMed PMID: 2903673]